EUCTR2010-020167-20-IT进行中（未招募）不适用
Pharmacokinetics, efficacy, tolerability and safety evaluation of the therapy with subcutaneous immunoglobulin in the treatment of hypo or agammaglobulinaemic patients. Open label phase II/III study - ND
KEDRIO0 个研究点开始时间: 2010年10月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients with hypogammaglobulinaemia or agammaglobulinaemia; 2. Male or female with age from 2 to less than 61 years; 3. Patients already on treatment with immunoglobulin preparation (intravenous or subcutaneous) for at least 6 months, with documented IgG trough levels > 500 mg/dl; 4. Written informed consent and authorization for treatment of personal data
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patient not previously treated with immunoglobulin; 2. Patient is positive for HIV, HCV, or HBV; 3. Pregnant or breastfeeding women or women of childbearing potential not using adequate contraception; 4. Patient presents severe systemic diseases or associated conditions contraindicating the use of immunoglobulin (thrombocytopenia gravis, coagulation disorders, allergic reactions to Ig) or record of severe adverse reactions to blood or blood derivatives; 5. Acute bacterial infections that required treatment with intravenous antibiotics in the previous 1 week; 6. Treatment with immunosuppressive drugs in the previous 3 weeks; 7. Allogeneic bone marrow transplantation during the last year before inclusion; 8. Nephrotic syndrome characterized by proteinuria = 3.5 g/24h, serum protein levels < 60 g/l or serum albumin levels < 30 g/l; 9. Chronic renal failure or creatinine clearance < 80 ml/min according to Cockroft formula; 10. History of heart failure (NYHA III/IV), cardiomyopathy, congestive heart failure, severe hypertension, cancer of lymphoid cells, hypoalbuminemia, protein-dispersive enteropathy; 11. Associated condition of chronic broncho-pneumopathy; 12. Presence of any conditions which, in the investigator’s judgment, may interfere with study objective evaluation; 13. Subject participated in another clinical study during the month prior to study start date (the subject received other study drugs during the last 30 days)or refused to sign the written informed consent required for participation
研究者
相似试验
进行中（未招募）
1 期
Efficacy, Safety, Tolerability and Pharmacokinetics of EXN-32 and EXN-44 in patients with Parkinson¿s Disease experiencing motor fluctuationsParkinson's Desease (PD)MedDRA version: 21.1Level: LLTClassification code 10013113Term: Disease Parkinson'sSystem Organ Class: 100000004852EUCTR2017-000262-30-ITDR. REDDY’S LABORATORIES LIMITED18
招募中
不适用
Safety, tolerability, efficacy and pharmacokinetic study of increasing doses of B26826 in adult patients with known or suspected intracranial lesions referred for contrast-enhanced MRI of the brain.Intracraniële laesies verwezen voor contrastverbeterde MRI van de hersenencontrast mediumintracranial lesionsNL-OMON54381Bracco Imaging S.pA.12
进行中（未招募）
不适用
Efficacy, safety, tolerability and pharmacokinetics of concomitant administration of tramadol with duloxetine or pregabalin: a randomized controlled flexible-dose study in patients with neuropathic paiG53.0 Vyöruusun jälkeinen hermosärkyG63.2 Diabeteksen monihermosairausMedDRA version: 9.1Level: LLTClassification code 10036377Term: Postherpetic polyneuropathyMedDRA version: 9.1Level: LLTClassification code 10012680Term: Diabetic neuropathyEUCTR2009-013061-26-FIniversity of Turku40
招募中
3 期
A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With systemic juvenile idiopathic arthritis (sJIA)CTRI/2022/03/040770Pfizer Inc
招募中
不适用
Safety, tolerability, pharmacokinetic and pharmacodynamic effects of single and multiple escalating doses of ODM-111 and effect of food on the pharmacokinetics of ODM-111 and pharmacokinetic drug-drug interaction potential of ODM-111Chronic-/neuropathic pain10029305NL-OMON53911Orion Corporation182